In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $14.00. The company's shares closed last Thursday at $7.37. According to TipRanks.com, Belanger is a 4-star analyst with an average return of 3.9% and a 45.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $15.33, a 125.4% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-sticks-to-their-buy-rating-for-aerie-pharma-aeri-2?utm_source=advfn.com&utm_medium=referral
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfico Histórico do Ativo
De Set 2022 até Out 2022 Click aqui para mais gráficos Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfico Histórico do Ativo
De Out 2021 até Out 2022 Click aqui para mais gráficos Aerie Pharmaceuticals.